Lab Literacy / The VAT Connection: Why Visceral Fat Is the Measured Endpoint
8 min readMost drug approvals are measured in blood. A cholesterol drug gets judged on LDL. A diabetes drug on HbA1c. The endpoint lives in a lab value, because lab values are cheap, repeatable, and standardizable across thousands of patients.
Tesamorelin's FDA approval was measured with a CT scanner.
Not weight. Not BMI. Not waist circumference, although that was part of the entry criteria. The primary endpoint was a cross-sectional image taken at the L4-L5 vertebra, measuring the area of fat packed around the internal organs — visceral adipose tissue, or VAT.
That choice drove the trial design, the enrollment criteria, and the lab panel. Understanding why tells you something important about how body-composition research actually works.
Two people can carry the same BMI and look nothing alike. One stores fat under the skin — subcutaneous, relatively metabolically quiet. The other packs it around the liver, intestines, and kidneys — visceral, metabolically active, and strongly associated with insulin resistance, dyslipidemia, and cardiovascular risk.
The distinction matters because most simple measurements cannot tell them apart.
| Measure | What it captures | Can it isolate VAT? |
|---|---|---|
| BMI | Total mass relative to height | No — cannot distinguish fat from lean, or visceral from subcutaneous |
| Waist circumference | Girth at the umbilicus | Partially — correlated with VAT but confounded by subcutaneous fat and frame size |
| Waist-to-hip ratio | Relative fat distribution | Better than waist alone, still indirect |
| DEXA | Whole-body fat, lean mass, bone | Regional estimates only — cannot isolate VAT from subcutaneous |
| CT @ L4-L5 | Cross-sectional tissue area by density | Yes — directly quantifies VAT area in cm² |
CT scanning at the L4-L5 level is the research gold standard for quantifying visceral fat. It distinguishes visceral from subcutaneous fat by tissue density on the image. It is more expensive and involves radiation exposure, which is why it does not appear in routine clinical care — but for a compound whose mechanism targets visceral fat specifically, it was the only endpoint that could directly measure whether the drug worked.
The pivotal tesamorelin trial enrolled HIV-positive adults on stable antiretroviral therapy who had excess abdominal fat — a condition called HIV-associated lipodystrophy. Antiretroviral drugs in earlier treatment eras caused a characteristic redistribution: fat wasting in the face and limbs paired with accumulation in the abdomen.
Entry required a waist circumference of at least 95 cm in men or 94 cm in women, plus an elevated waist-to-hip ratio. Additional lab gates: CD4 count above 100, viral load below 10,000 copies/mL. The trial excluded anyone who had used growth hormone or growth-hormone-releasing factor within six months, anyone on antidiabetic agents, anyone with insulin-treated type 2 diabetes, active malignancy, or untreated hypertension.
The primary endpoint: percent change in VAT area, measured by CT at L4-L5, at 26 weeks.
The result: approximately 15% reduction in VAT at 26 weeks, extending to roughly 18% at 52 weeks. Secondary endpoints showed triglyceride reduction — consistent with the relationship between visceral fat and the atherogenic lipid pattern of high triglycerides paired with low HDL-C.
No other peptide has an FDA approval grounded in a body-composition imaging endpoint. Tesamorelin is the only one.
A drug that reduces overall weight produces a number on a scale, but a scale cannot distinguish what was lost. Fat, lean tissue, and water all contribute to weight. For a compound targeting a specific fat depot — visceral adipose tissue — a scale would be noise.
The trial design needed an endpoint that could answer one question: did the visceral fat shrink? CT was the only widely validated method that could.
The entry criteria reinforce this logic. Waist circumference served as the screening tool — cheap, non-invasive, good enough to identify people likely to have elevated VAT. But waist alone is confounded by subcutaneous fat. A 100 cm waist could reflect mostly subcutaneous deposition with normal VAT, or mostly visceral accumulation. CT resolved that ambiguity at enrollment and again at the endpoint.
The imaging endpoint sat inside a broader lab framework. None of these labs replaced the scan — the scan was the primary endpoint, full stop. The labs provided context.
The labs answered the questions the scan could not: is VAT reduction accompanied by the metabolic improvements you would expect? Is IGF-1 moving in the expected range? Is glucose staying under control? The scan answered the one question the labs could not: did the fat depot itself shrink?
When you encounter a body-composition study, the first question is: how was body composition actually measured?
BMI is a screening tool, not an outcome measure. Waist circumference is better but indirect. DEXA gives regional estimates. Only CT or MRI at a standardized anatomical level can directly quantify visceral fat — and that is the measure the FDA used when it approved tesamorelin.
Any study claiming to measure "fat loss" without specifying the method — or using only a scale — is not measuring what it claims. The tesamorelin program is the case study in why that distinction matters: the drug reduces visceral fat specifically, and only an imaging endpoint could prove it.
This article is for educational purposes and is not medical advice. It describes how published clinical trials measured body-composition endpoints. It does not recommend any peptide, test, or protocol. Decisions about treatment belong with a qualified clinician who knows your medical history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.